This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Cytos Biotechnology Ag. Active years: 2009.
Company Filing History:
Years Active: 2009
Title: Pioneering Innovator: Andreas Cornelius Revolutionizing Vaccine Development
Introduction:
Andreas Cornelius, a visionary inventor based in Regensdorf, Switzerland, is making significant strides in the field of vaccine development. With a passion for innovation and a commitment to creating a sustainable future, Cornelius has established himself as a leading figure in the world of immunostimulatory research.
Latest Patents:
Cornelius holds a groundbreaking patent titled "Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use." This invention revolutionizes the use of virus-like particles (VLPs) by enhancing their immunogenicity through the loading of DNA oligonucleotides containing non-methylated C and G (CpGs). The CpG-VLPs developed by Cornelius induce robust B and T cell responses, making them ideal candidates for vaccines against allergies, tumors, chronic viral diseases, and other conditions.
Career Highlights:
With a track record of innovation, Andreas Cornelius is currently associated with Cytos Biotechnology AG, a leading biotechnology company. At Cytos Biotechnology AG, he continues to push the boundaries of vaccine development and immunotherapy, contributing significantly to the advancement of medical science.
Collaborations:
In his pursuit of pioneering research, Cornelius collaborates with accomplished professionals in the field. Notable colleagues include Vania Manolova and Martin F. Bachmann, who bring their expertise to the table, further enriching the innovative work being done in vaccine development.
Conclusion:
Andreas Cornelius emerges as a trailblazing inventor whose dedication to scientific advancement and commitment to transformative innovation are evident in his groundbreaking research. His contributions to the field of immunostimulatory technology position him as a visionary driving positive change in the landscape of vaccine development. As he continues to explore new possibilities and push the boundaries of what is achievable, Cornelius inspires aspiring inventors worldwide to pursue their creative visions for a brighter, healthier future.